Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Genetically targeted clinical trials in parkinson’s disease: Learning from the successes made in oncology

Research output: Contribution to journalReviewResearchpeer-review

DOI

  1. Cathepsin C Regulates Cytokine-Induced Apoptosis in β-Cell Model Systems

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Stable Longitudinal Methylation Levels at the CpG Sites Flanking the CTG Repeat of DMPK in Patients with Myotonic Dystrophy Type 1

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. An Expanded Multi-Organ Disease Phenotype Associated with Mutations in YARS

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Why Do Women with Eating Disorders Decline Treatment? A Qualitative Study of Barriers to Specialized Eating Disorder Treatment

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Inpatient weight restoration treatment is associated with decrease in post-meal anxiety

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Why do women with eating disorders decline treatment? A qualitative study of barriers to specialized eating disorder treatment

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Inpatient Weight Restoration Treatment Is Associated with Decrease in Post-Meal Anxiety

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Disturbances in the experiences of embodiment related to attachment, mentalization and self-objectification in anorexia nervosa

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Clinical trials in neurodegenerative disorders have been associated with high rate of failures, while in oncology, the implementation of precision medicine and focus on genetically defined subtypes of disease and targets for drug development have seen an unprecedented success. With more than 20 genes associated with Parkinson’s disease (PD), most of which are highly penetrant and often cause early onset or atypical signs and symptoms, and an increasing understanding of the associated pathophysiology culminating in dopaminergic neurodegeneration, applying the technologies and designs into the field of neurodegeneration seems a logical step. This review describes some of the methods used in oncology clinical trials and some attempts in Parkinson’s disease and the potential of further implementing genetics, biomarkers and smart clinical trial designs in this disease area.

Original languageEnglish
Article number1529
JournalGenes
Volume12
Issue number10
ISSN2073-4425
DOIs
Publication statusPublished - Oct 2021

Bibliographical note

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.

    Research areas

  • Clinical trials, Genetic targets, Neurodegenerative disorders, Oncology, Parkinson’s disease, Precision medicine

ID: 68497908